The use of radioactive 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) in the assay of androgen receptors
- PMID: 6333679
- DOI: 10.1002/pros.2990050603
The use of radioactive 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) in the assay of androgen receptors
Abstract
Tritiated 7 alpha, 17 alpha-dimethyl-19-nortestosterone (DMNT; mibolerone), a synthetic androgen stable to metabolic conversion in the rat ventral prostate, is an excellent radioactive ligand for the quantitation and characterization of androgen receptors in prostate, liver, and cultured cells. DMNT is more receptor-selective than 17 alpha-methyl-17 beta-hydroxy-estra-4,9,11-trien-3-one (R1881); DMNT interacts with glucocorticoid and progestin receptors much less strongly than R1881. Unlike 5 alpha-dihydrotestosterone, DMNT does not bind tightly to testosterone-estradiol binding globulin of human serum. The hydroxylapatite-filter assay we employed can clearly distinguish between DMNT binding to androgen receptors of rat ventral prostate and interaction of DMNT with androgen binding protein of epididymides. The prostate cytosol (3H)DMNT-receptor complex sediments in two forms (4 and 8 S) in a low salt medium. In 0.4 M KCl, both the prostate cytosol and nuclear (3H)DMNT-receptor complexes migrated as 3-4 S components. The formation of both the cytosol and nuclear DMNT-receptor complexes is inhibited by antiandrogens and 17 beta-estradiol.
Similar articles
-
Binding of 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) to androgen and progesterone receptors in human and animal tissues.Endocrinology. 1986 Apr;118(4):1327-33. doi: 10.1210/endo-118-4-1327. Endocrinology. 1986. PMID: 2419120
-
Characterization of steroid receptors in human prostate using mibolerone.Prostate. 1986;8(3):241-53. doi: 10.1002/pros.2990080305. Prostate. 1986. PMID: 2422638
-
Characterization of the cytosol androgen receptor of the human prostate.J Clin Endocrinol Metab. 1983 Jan;56(1):113-20. doi: 10.1210/jcem-56-1-113. J Clin Endocrinol Metab. 1983. PMID: 6183286
-
Clinical applications and value of receptor levels in treatment of prostate cancer.Prostate. 1984;5(5):477-83. doi: 10.1002/pros.2990050503. Prostate. 1984. PMID: 6384975 Review.
-
Active forms and biodynamics of the androgen-receptor in various target tissues.Curr Top Mol Endocrinol. 1976;4:139-51. doi: 10.1007/978-1-4684-2601-4_12. Curr Top Mol Endocrinol. 1976. PMID: 800356 Review. No abstract available.
Cited by
-
Soluble and nuclear type I and II androgen-binding sites in benign hyperplasia and cancer of the human prostate.Urol Res. 1992;20(2):127-32. doi: 10.1007/BF00296524. Urol Res. 1992. PMID: 1372770
-
Autoimmune anti-androgen-receptor antibodies in human serum.Proc Natl Acad Sci U S A. 1985 Dec;82(24):8345-8. doi: 10.1073/pnas.82.24.8345. Proc Natl Acad Sci U S A. 1985. PMID: 3866227 Free PMC article.
-
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.Mol Cancer Ther. 2017 Aug;16(8):1680-1692. doi: 10.1158/1535-7163.MCT-16-0923. Epub 2017 Apr 20. Mol Cancer Ther. 2017. PMID: 28428441 Free PMC article.
-
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007. Sci Rep. 2015. PMID: 26137992 Free PMC article.
-
A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).Br J Cancer. 1989 Nov;60(5):664-8. doi: 10.1038/bjc.1989.336. Br J Cancer. 1989. PMID: 2803943 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources